AUTHORS
Elena Sofia Vivona, MD, Sarah Adams, BS2, Mosinmiloluwa Adewunmi3, Aimee Zhang4, Pankaj Sharma, PhD5, Stefano Rivella, PhD6, Peter Kurre, MD7
AFFILIATIONS
1 Children's Hospital of Philadelphia, Philadelphia, United States, Pediatric Residency Program, University of Milan, Milan, Italy
2 Children's Hospital of Philadelphia, Philadelphia, United States
3 Children's Hospital of Philadelphia, Philadelphia, United States
4 Children's Hospital of Philadelphia, Philadelphia, United States
5 Children's Hospital of Philadelphia, Philadelphia, United States
6 Children's Hospital of Philadelphia, Philadelphia, United States, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States, The Children’s Hospital of Philadelphia, Philadelphia, United States
7 Children's Hospital of Philadelphia, Philadelphia, United States, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States, The Children’s Hospital of Philadelphia, Philadelphia, United States
ABSTRACT
Fanconi Anemia (FA) is the most common inherited bone marrow failure (BMF) syndrome. It’s unknown whether the cause of endogenous BMF is related to the nuclear function of FA proteins in DNA repair. Our own and other groups have demonstrated that FA hematopoietic stem and progenitor cell (HSPC) loss is associated with constitutively active MYC, and that reducing MYC activity rescues long-term hematopoietic stem cell (LT-HSCs) function in FA mice. Among validated MYC targets, our analysis focused on transferrin receptor 1 (TFRC-1, CD71), as it is a central regulator of cellular iron homeostasis. Iron plays a critical role in regulating HSC metabolism and quiescence; however, excess intracellular iron sensitizes cells to lipid peroxidation and ferroptosis. We therefore hypothesized that constitutively active MYC/CD71 will alter homeostatic regulation of iron metabolism, leaving FA HSPCs vulnerable to accumulating lipid reactive oxygen species (ROS) that may compromise their regenerative reserve. To validate key regulatory steps, we used immortalized murine HPC-7 cells, an established model for studying HSPC function. First, to distinguish MYC-driven changes in iron metabolism from the FA phenotype, we generated (non-FA) HPC-7 cells overexpressing MYC and confirmed an increased level of CD71 surface expression. Iron loading in MYC-overexpressing HPC-7 cells with ferric ammonium citrate (FAC) increased the labile iron pool (LIP) and downregulated CD71, whereas desferoxamine (DFO) treatment increased CD71. These findings suggest that MYC overexpression itself maintains canonical iron responses. Evaluation of CD71 expression in primary murine Fancd2-KO LT-HSCs and MPP3 populations, which we have previously demonstrated to constitutively overexpress c-MYC, revealed a significant 2-fold increase at baseline compared to wild type (WT) controls. WT HSPC are sensitive to environmental iron availability, and we find that iron restriction ex vivo improves expansion in a dose-responsive manner. However, when we assessed the dynamic regulation of CD71 in Fancd2-KO, LT-HSCs failed to downregulate surface levels of CD71 in response to FAC treatment and, unlike WT, displayed only a minimal additional increase in response to DFO, suggesting that FA HSCs exist in a MYC-locked, CD71-high state, unresponsive to changes in cellular LIP. The toxicity of excess iron is in part related to its role in generating reactive oxygen species (ROS). Consistent with the known sensitivity of FA HSPC, we found elevated baseline lipid peroxidation in FA HSPCs relative to WT HSPCs and an exaggerated response to erastin, a potent ferroptosis inducer. Strikingly, FAC treatment also resulted in an increase in lipid peroxidation in Fancd2-deficient LT-HSCs and MPP2 progenitors, suggesting a generally heightened susceptibility to iron-dependent generation of lipid ROS. These results align well with our previous finding of in vivo LT-HSC rescue after treatment with tauroursodeoxycholic acid (TUDCA), which limits lipid peroxidation through iron scavenging. Ongoing studies will clarify whether lipid ROS metabolites exert toxicity on murine FA HSC by exacerbating mitochondrial dysfunction, through direct genotoxic stress, or a combination of both. Translational support for a role of iron metabolism in FA pathophysiology comes from clinical trials of eltrombopag, a thrombopoietin receptor agonist with iron-chelating and antioxidant properties, which has been associated with increased CD34+ cell counts in FA patients. We propose that a detailed understanding of iron metabolism may offer insight into BMF in FA and can be leveraged to preserve hematopoietic function in FA patients.
DISCLOSURES
Elena Sofia Vivona, MD: No relevant conflicts of interest to declare.